Postby Ajane » Sat Jan 14, 2017 8:29 am
Alexandria, My "journey" is different than most, but I thought I would let you know that I'm KRAS wild with BRAF2 mutation. I achieved a complete pathological response after an initial six weeks of Xeloda-Rad for an ultra-low tumor some 42 months ago. Although I've since had two distant recurrences, I've remained cancer free locally. Diagnosed as stage 1 initially, I had the less-invasive transanal endoscopic surgery post chemorad instead of the APR surgery. In hindsight, had I chosen the much aggressive surgery, its possible I might have been able to avoid distant recurrences.
Wishing you the best possible results, Jane
7/13, T2, G3, Ultra-low. CEA 5.7 KRAS Wild, MSS
8-9/13 6 wks Xeloda/radiation
12/13 TEM pCR NED
5/15 CEA 4.6 PET 1.5 cm met, UL Lobectomy
6-10/15: Rounds 1-2 Xelox+Avastin; 3-8 Folfox+Avastin
10/15-4/16: 12 rounds Avastin
9/2016 CEA 4.2, 12 mm AP node
11/2016 CEA 4.3. PET/CT. 16mm AP nodal met removed
4 wks chemorad
2/2017 NED CEA 2.4
Carafate to tx esophageal ulcers caused by rad
Avastin maintenance postponed
2 Corinthians 12:9